BioLineRx Ltd. (BLRX)
BioLineRx Statistics
Share Statistics
BioLineRx has 3.72M shares outstanding. The number of shares has increased by 74.04% in one year.
| Shares Outstanding | 3.72M |
| Shares Change (YoY) | 74.04% |
| Shares Change (QoQ) | 34.18% |
| Owned by Institutions (%) | 0% |
| Shares Floating | 3.7M |
| Failed to Deliver (FTD) Shares | 1.57K |
| FTD / Avg. Volume | 3.28% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -1.85 and the forward PE ratio is -2.3. BioLineRx's PEG ratio is 0.
| PE Ratio | -1.85 |
| Forward PE | -2.3 |
| PS Ratio | 0.59 |
| Forward PS | 0.9 |
| PB Ratio | 1.27 |
| P/FCF Ratio | -0.39 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for BioLineRx.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.76, with a Debt / Equity ratio of 1.12.
| Current Ratio | 1.76 |
| Quick Ratio | 1.56 |
| Debt / Equity | 1.12 |
| Debt / EBITDA | 3.77 |
| Debt / FCF | -0.34 |
| Interest Coverage | -2.24 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.03M |
| Profits Per Employee | $-329.32K |
| Employee Count | 28 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 2.95 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -86.97% in the last 52 weeks. The beta is 0.95, so BioLineRx's price volatility has been higher than the market average.
| Beta | 0.95 |
| 52-Week Price Change | -86.97% |
| 50-Day Moving Average | 3.13 |
| 200-Day Moving Average | 13.82 |
| Relative Strength Index (RSI) | 62.12 |
| Average Volume (20 Days) | 48.01K |
Income Statement
In the last 12 months, BioLineRx had revenue of 28.94M and earned -9.22M in profits. Earnings per share was -6.
| Revenue | 28.94M |
| Gross Profit | 19.68M |
| Operating Income | -20.41M |
| Net Income | -9.22M |
| EBITDA | 3.99M |
| EBIT | -147K |
| Earnings Per Share (EPS) | -6 |
Balance Sheet
The company has 10.44M in cash and 15.04M in debt, giving a net cash position of -4.6M.
| Cash & Cash Equivalents | 10.44M |
| Total Debt | 15.04M |
| Net Cash | -4.6M |
| Retained Earnings | -399.83M |
| Total Assets | 38.91M |
| Working Capital | 11.7M |
Cash Flow
In the last 12 months, operating cash flow was -43.87M and capital expenditures -54K, giving a free cash flow of -43.93M.
| Operating Cash Flow | -43.87M |
| Capital Expenditures | -54K |
| Free Cash Flow | -43.93M |
| FCF Per Share | -1.47 |
Margins
Gross margin is 67.99%, with operating and profit margins of -70.52% and -31.86%.
| Gross Margin | 67.99% |
| Operating Margin | -70.52% |
| Pretax Margin | -31.86% |
| Profit Margin | -31.86% |
| EBITDA Margin | 13.79% |
| EBIT Margin | -70.52% |
| FCF Margin | -151.79% |
Dividends & Yields
BLRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BLRX is $26, which is 655.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $26 |
| Price Target Difference | 655.8% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jan 30, 2025. It was a backward split with a ratio of 1:40.
| Last Split Date | Jan 30, 2025 |
| Split Type | backward |
| Split Ratio | 1:40 |
Scores
| Altman Z-Score | -13.01 |
| Piotroski F-Score | 3 |